Myelodysplastic syndromes (MDS) are a group of myeloid neoplasms characterized by cytopenias and a risk of progression to acute myeloid leukemia (AML). While development in lower-risk patients seeks to decrease transfusion burden, multiple mechanisms are being explored to enhance the efficacy of hypomethylating agents in higher-risk patients. With 2020 bringing the first new drug approvals for MDS in over a decade, and readouts for multiple registrational trials on the horizon, the MDS landscape is rapidly evolving.
Oncology Resource Group (ONCrg) is a team of expert analysts who rigorously evaluate the latest corporate reports, news, and data presentations to distill out important advances in complex therapeutic areas. Our comprehensive medical congress coverage, and continuous market surveillance put these advances into the context of an overarching competitive landscape in MDS to help guide strategic and tactical commercial development decisions for market participants.